A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Sponsor: Regeneron Pharmaceuticals
Listed as NCT06836609, this observational or N/A phase trial focuses on Metabolic Dysfunction-Associated Steatohepatitis and Metabolic Dysfunction-Associated Steatotic Liver Disease and remains actively recruiting participants. Sponsored by Regeneron Pharmaceuticals, it has been updated 5 times since 2025, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
-
Apr 17, 2026 — Apr 28, 2026 [daily]
Recruiting
Phase: PHASE1 → None
-
Oct 2025 — Apr 2026 [monthly]
Recruiting PHASE1
-
Jun 2025 — Oct 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting liver conditions caused by having too much fat in the liver. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How the study drug works to change liver fat content * How much study drug and study drug metabolites (byproducts of the body breaking down the study drug) are in the blood at different times
Contact Information
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .